文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

瑞博西利对脓毒症诱导急性肾损伤的保护作用及机制

[Protective effect and mechanism of Ribociclib on sepsis induced-acute kidney injury].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论小鼠与细胞实验显示,瑞博西利预处理可减轻脓毒症诱导的急性肾损伤,AKT/mTOR通路可能参与其中。

该研究采用盲肠结扎穿孔(CLP)脓毒症小鼠模型和脂多糖(LPS)刺激的小鼠肾小管上皮细胞(TCMK-1)模型,观察瑞博西利对脓毒症诱导急性肾损伤的作用及机制。动物实验中,瑞博西利预处理组较CLP组肾脏病理评分显著降低(1.48±0.16 vs. 2.68±0.16,P<0.01),肾组织TNF-α、IL-6水平显著下降,p-Rb表达进一步降低,Bcl-2/Bax比值升高。细胞实验中,瑞博西利+LPS组较LPS组TNF-α、IL-6释放减少,p-Rb表达进一步降低,Bcl-2/Bax和LC3b II/I比值升高,p62、p-AKT、p-mTOR表达降低。作者认为瑞博西利预处理可改善脓毒症诱导的急性肾损伤,AKT/mTOR通路可能参与其保护作用。

要点

  • CLP脓毒症小鼠中,瑞博西利150 mg/kg术前12小时给药,肾脏病理评分较CLP组显著降低(1.48±0.16 vs. 2.68±0.16,P<0.01)。
  • 瑞博西利预处理组肾组织TNF-α较CLP组显著降低(340.55±34.96 ng/g vs. 745.08±58.86 ng/g,P<0.01),IL-6亦显著降低(17.33±1.01 mg/g vs. 114.20±20.49 mg/g,P<0.01)。
  • 瑞博西利+LPS组较LPS组细胞培养上清TNF-α降低(2.73±0.23 ng/L vs. 4.96±0.10 ng/L,P<0.01),IL-6降低(36.05±5.83 ng/L vs. 53.78±24.08 ng/L,P<0.01)。
  • 瑞博西利+LPS组较LPS组p-AKT/β-tubulin(0.61±0.03 vs. 1.20±0.06)和p-mTOR/β-tubulin(0.50±0.05 vs. 1.15±0.08)表达降低,均P<0.01。
  • 作者认为AKT/mTOR通路可能参与瑞博西利对脓毒症诱导急性肾损伤的保护作用。

适用人群与场景

  • 动物实验:成年雄性C57BL/6小鼠,采用盲肠结扎穿孔(CLP)诱导脓毒症模型。
  • 细胞实验:小鼠肾小管上皮细胞系(TCMK-1),采用脂多糖(LPS)刺激模拟炎症损伤。

处置流程与药物剂量

  • 动物实验:瑞博西利预处理组在CLP前12小时给予瑞博西利150 mg/kg(原文未写明给药途径)。
  • 动物实验:假手术组在术前12小时给予乳酸缓冲液(原文未写明剂量与途径);瑞博西利对照组给予瑞博西利150 mg/kg(原文未写明给药途径)。
  • 细胞实验:瑞博西利组以5 μmol/L瑞博西利处理24小时;LPS组以200 mg/L LPS处理6小时;瑞博西利+LPS组先以5 μmol/L瑞博西利暴露18小时,再换含5 μmol/L瑞博西利和200 mg/L LPS的培养基处理6小时。

研究设计与关键结果

  • 动物实验:与假手术组比较,CLP组小鼠肾组织明显损伤,TNF-α和IL-6水平升高,p-Rb表达及Bcl-2/Bax比值降低;瑞博西利对照组与假手术组各指标无显著差异。
  • 动物实验:与CLP组比较,瑞博西利预处理组肾脏损伤显著减轻,病理评分显著降低(1.48±0.16 vs. 2.68±0.16,P<0.01)。
  • 动物实验:与CLP组比较,瑞博西利预处理组肾匀浆TNF-α(340.55±34.96 ng/g vs. 745.08±58.86 ng/g)和IL-6(17.33±1.01 mg/g vs. 114.20±20.49 mg/g)均显著降低,均P<0.01。
  • 动物实验:与CLP组比较,瑞博西利预处理组p-Rb/β-tubulin进一步降低(0.14±0.01 vs. 0.73±0.06,P<0.01),Bcl-2/Bax比值升高(0.89±0.06 vs. 0.62±0.10,P<0.01)。
  • 细胞实验:与对照组比较,LPS组TNF-α和IL-6释放增加,p-Rb表达降低,Bcl-2/Bax和LC3b II/I比值降低,p62、p-AKT和p-mTOR表达升高;TCMK-1细胞经瑞博西利处理后p-Rb表达降低。
  • 细胞实验:与LPS组比较,瑞博西利+LPS组TNF-α降低(2.73±0.23 ng/L vs. 4.96±0.10 ng/L,P<0.01),IL-6降低(36.05±5.83 ng/L vs. 53.78±24.08 ng/L,P<0.01)。
  • 细胞实验:与LPS组比较,瑞博西利+LPS组p-Rb/β-tubulin进一步降低(0.25±0.05 vs. 0.65±0.05,P<0.01),Bcl-2/Bax比值升高(1.01±0.07 vs. 0.73±0.05,P<0.05),LC3b II/I比值升高(2.08±0.31 vs. 1.04±0.01,P<0.05)。
  • 细胞实验:与LPS组比较,瑞博西利+LPS组p62/β-tubulin(0.59±0.01 vs. 1.09±0.08)、p-AKT/β-tubulin(0.61±0.03 vs. 1.20±0.06)、p-mTOR/β-tubulin(0.50±0.05 vs. 1.15±0.08)表达均降低,均P<0.01。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠CLP脓毒症模型)与体外细胞实验(TCMK-1细胞LPS刺激模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究为动物与细胞水平的机制探索,作者认为瑞博西利预处理可改善脓毒症诱导的急性肾损伤,AKT/mTOR通路可能参与其保护作用,尚不能据此形成急诊或ICU床旁用药推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the role of Ribociclib in sepsis induced-acute kidney injury (AKI) and its possible mechanisms.

METHODS: (1) Twenty adult male C57BL/6 mice were divided into sham operation group (Sham group; only open the abdomen without ligating or perforating the cecum, administered with sodium lactate buffer 12 hours before the sham operation), Ribociclib control group (administered with 150 mg/kg Ribociclib), cecal ligation and puncture (CLP) group (sepsis model induced by CLP; lactate buffer was given by intragastric administration 12 hours before CLP), and Ribociclib pretreatment group (administered with 150 mg/kg Ribociclib 12 hours before CLP) according to random number table, with 5 mice in each group. Kidneys were harvested 12 hours after the operation. Pathological changes in kidney were observed by hematoxylin-eosin (HE) staining. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels in mice kidney homogenate were measured by enzyme linked immunosorbent assay (ELISA). Western Blot was used to detect the expression of cell cycle-related protein phosphorylate retinoblastoma protein (p-Rb), apoptosis-related protein Bcl-2 and Bax. (2) Mouse renal tubular epithelial (TCMK-1) cell line was used for in vitro experiment. The cells were divided into control group, Ribociclib group (treated with 5 μmol/L Ribociclib for 24 hours), lipopolysaccharide (LPS) group (treated with 200 mg/L LPS for 6 hours), Ribociclib+LPS group (replaced with the medium containing 5 μmol/L Ribociclib and 200 mg/L LPS for 6 hours after exposing with 5 μmol/L Ribociclib for 18 hours). Inflammatory cytokines in cell culture medium were detected by ELISA. The expression of p-Rb, Bcl-2 and Bax, autophagy-related proteins microtubule associated protein 1 light chain LC3b (LC3b II, LC3b I) and p62, phosphate protein kinase B (p-AKT), phosphorylated mammalian target of rapamycin (p-mTOR) were measured by Western Blot.

RESULTS: (1) Animal experiments showed that, compared with the Sham group, the kidney tissue of mice were significantly damaged, the levels of TNF-α and IL-6 were increased, the expressions of p-Rb and Bcl-2/Bax ratio were decreased in kidney tissue in CLP group; but there was no significant difference in indexes between Ribociclib control group and Sham group. Compared with the CLP group, kidney injury in mice pretreated with Ribociclib was significantly ameliorated, the pathological score was significantly decreased (1.48±0.16 vs. 2.68±0.16, P < 0.01), the levels of TNF-α and IL-6 in kidney homogenate were significantly decreased [TNF-α (ng/g): 340.55±34.96 vs. 745.08±58.86, IL-6 (mg/g): 17.33±1.01 vs. 114.20±20.49, both P < 0.01], the expression of p-Rb was furtherly decreased (p-Rb/β-tubulin: 0.14±0.01 vs. 0.73±0.06, P < 0.01), Bcl-2/Bax ratio was increased (0.89±0.06 vs. 0.62±0.10, P < 0.01). (2) In vitro experiments showed that, compared with the control group, the releases of TNF-α and IL-6 were increased, the expression of p-Rb was decreased, the ratios of Bcl-2/Bax and LC3b II/I were decreased, the expressions of p62, p-AKT and p-mTOR were increased in LPS group; the expression of p-Rb was decreased after Ribociclib treatment in TCMK-1 cells. Compared with the LPS group, TNF-α and IL-6 were decreased [TNF-α (ng/L): 2.73±0.23 vs. 4.96±0.10, IL-6 (ng/L): 36.05±5.83 vs. 53.78±24.08, both P < 0.01], the expression of p-Rb was furtherly decreased (p-Rb/β-tubulin: 0.25±0.05 vs. 0.65±0.05, P < 0.01), the ratios of Bcl-2/Bax and LC3b II/I were increased (Bcl-2/Bax: 1.01±0.07 vs. 0.73±0.05, LC3b II/I: 2.08±0.31 vs. 1.04±0.01, both P < 0.05), the expressions of p62, p-AKT and p-mTOR were decreased (p62/β-tubulin: 0.59±0.01 vs. 1.09±0.08, p-AKT/β-tubulin: 0.61±0.03 vs. 1.20±0.06, p-mTOR/β-tubulin: 0.50±0.05 vs. 1.15±0.08, all P < 0.01) in the Ribociclib+LPS group.

CONCLUSIONS: Ribociclib pretreatment ameliorated sepsis-induced AKI and AKT/mTOR pathway may be involved in the protective role of Ribociclib on kidney.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Wang Q, Gong X, Jia J, et al. [Protective effect and mechanism of Ribociclib on sepsis induced-acute kidney injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32275007. doi:10.3760/cma.j.cn121430-20200108-00038

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。